MWMatthijs R. A. Welkers

Matthijs R. A. Welkers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthijs R. A. Welkers has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First detection and autochthonous transmission of monkeypox virus clade Ib in the Netherlands, October to November, 2025

    by Jelte Elsinga, Celine van de Ven, Anne de Vries, Hester Coppoolse, Mariska Petrignani, Brigitte van Cleef, Riemer van Markus, Nora Carpay, Catharina E van Ewijk, Sjoerd Rebers, et al.

    In October–November 2025, eight autochthonous cases of monkeypox (MPXV) clade Ib virus infection were reported in the Netherlands. All cases were men who have sex with men aged 25–65; none required hospital admission or antiviral treatment. Phylogenetic analysis combined with contact tracing suggest multiple introductions or cryptic circulation with onwards transmission within the community. Highly related international sequences were identified dating back to August 2025, indicating sustained global community transmission of clade Ib outside the African continent.


  • Open Access

    Scenarios of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022

    by Marc C Shamier, Luca M Zaeck, Hannelore M Götz, Bruno Vieyra, Babs E Verstrepen, Koen Wijnans, Matthijs Ra Welkers, Elske Hoornenborg, Brigitte Agl van Cleef, Martin E van Royen, et al.

    Background: Following the 2022–2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks. Aim: We combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate scenarios of future mpox outbreaks among men who have sex with men (MSM). Methods: Serum samples were obtained from 1,065 MSM attending Centres for Sexual Health (CSH) in Rotterdam or Amsterdam following the peak of the Dutch mpox outbreak and the introduction of vaccination. For MSM visiting the Rotterdam CSH, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)-specific IgG. These observations were combined with published data on serial interval and vaccine effectiveness to inform a stochastic transmission model that estimates the risk of future mpox outbreaks. Results: The seroprevalence of VACV-specific antibodies was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Transmission modelling showed that the impact of risk group vaccination on the original outbreak was likely small. However, assuming different scenarios, the number of mpox cases in a future outbreak would be markedly reduced because of vaccination. Simultaneously, the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis is a key component of any strategy to prevent new outbreaks. Conclusion: Our findings indicate a reduced likelihood of large future mpox outbreaks among MSM in the Netherlands under current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities and disease awareness.


  • Open Access

    Circulation, viral diversity and genomic rearrangement in mpox virus in the Netherlands during the 2022 outbreak and beyond

    by Leonard Schuele, Marjan Boter, David F. Nieuwenhuijse, Hannelore Götz, Ewout Fanoy, Henry de Vries, Bruno Vieyra, Roisin Bavalia, Elske Hoornenborg, Richard Molenkamp, et al.

    Mpox is an emerging zoonotic disease which has now spread to over 113 countries as of August 2023, with over 89,500 confirmed human cases. The Netherlands had one of the highest incidence rates in Europe during the peak of the outbreak. In this study, we generated 158 near‐complete mpox virus (MPXV) genomes (12.4% of nationwide cases) that were collected throughout the Netherlands from the start of the outbreak in May 2022 to August 2023 to track viral evolution and investigate outbreak dynamics. We detected 14 different viral lineages, suggesting multiple introductions followed by rapid initial spread within the country. The estimated evolutionary rate was relatively high compared to previously described in orthopoxvirus literature, with an estimated 11.58 mutations per year. Genomic rearrangement events occurred at a rate of 0.63% and featured a large deletion event. In addition, based on phylogenetics, we identified multiple potential transmission clusters which could be supported by direct source‐ and contact tracing data. This led to the identification of at least two main transmission locations at the beginning of the outbreak. We conclude that whole genome sequencing of MPXV is essential to enhance our understanding of outbreak dynamics and evolution of a relatively understudied and emerging zoonotic pathogen.


  • Open Access

    The risk of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data

    by Marc C. Shamier, Luca M. Zaeck, Hannelore M. Götz, Bruno Vieyra, Babs E. Verstrepen, Koen Wijnans, Matthijs R.A. Welkers, Elske Hoornenborg, Brigitte A.G.L. van Cleef, Martin E. van Royen, et al.

    Background In the wake of the 2022-2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks. Here, we combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate the risk of future mpox outbreaks among men who have sex with men (MSM). Methods Serum samples were obtained from 1,065 MSM visiting the Centres for Sexual Health (CSH) in Rotterdam or Amsterdam after the introduction of vaccination and the peak of the Dutch mpox outbreak. For MSM visiting the CSH in Rotterdam, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)- specific IgG; plaque reduction neutralization tests (PRNT) were performed on a selection of samples. These observations were combined with literature data on infection dynamics and vaccine effectiveness to inform a stochastic transmission model to estimate the risk on future mpox outbreaks. Findings The seroprevalence of VACV-specific IgG was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Based on the correlation between serological parameters, we identified confirmed MPXV infections and inferred nine undiagnosed infections in individuals without childhood smallpox vaccination in the Rotterdam cohort (5.1%). Transmission modelling showed that the overall number of mpox cases in new outbreaks would be low, but that the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis will be a key component of any strategy to prevent new outbreaks. Interpretation Our findings indicate a reduced likelihood of future mpox outbreaks among MSM in the Netherlands under the current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities, and disease awareness. Funding National Institute for Public Health and the Environment (RIVM), HORIZON-HLTH-2022-MPX-14 (101115188). Evidence before this study We searched PubMed from database inception to July 24th, 2023, using the search terms (“monkeypox” OR “mpox” OR “orthopoxvirus”) AND (“immunity” OR “antibodies” OR vaccin*) OR (model*) OR (“epidemiology” OR “outbreak”) OR (“seroprevalence” OR “serosurveillance”), with no date or language restrictions. We included the cited references of retrieved publications in our search. We found that there are crucial knowledge gaps with respect to monkeypox virus (MPXV)-specific immunity and the impact of risk group vaccination with third-generation smallpox vaccines on the prevention of future outbreaks. No seroprevalence studies following the 2022-2023 mpox outbreak have been published yet. Recent observational studies from Israel, the United Kingdom, and the United States reported adjusted vaccine effectiveness levels between 36% - 86% following one or two doses of MVA. After the massive 2022-2023 outbreak, the number of new cases is now at a very low level, although there are continouing reports of small clusters of infections, including breakthrough infections and re-infections. This long tail to the epi curve, raises concerns about the potential of future outbreaks. We found no studies that predicted the risk of future mpox outbreaks after risk group vaccination based on measured seroprevalence data. Added value of this study The primary goal of this study was to estimate the risk of future mpox outbreaks among men who have sex with men (MSM) in the Netherlands using mathematical modelling based on real-world data. To this end, we used a combination of serological assays to determine the presence and abundance of (functional) poxvirus-specific antibodies in a Dutch MSM cohort. Next, we demonstrate the impact of rapid diagnosis (followed by isolation) of mpox cases on the size and duration of future outbreaks employing a mathematical model. Implications of all the available evidence A seroprevalence level of approximately 45% among MSM in the Netherlands visiting the Centres for Sexual Health was found. Modelling showed that this seroprevalence level alone may not be sufficient to prevent future outbreaks, which emphasises the importance of continued disease awareness, and maintaining population immunity and diagnostic capacities. These insights have important implications for public health policy making and fill critical knowledge gaps to help inform surveillance activities and guide vaccination strategies.


  • Open Access

    A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2

    by Ellen C. Carbo, Kees Mourik, Stefan A. Boers, Bas Oude Munnink, David Nieuwenhuijse, Marcel Jonges, Matthijs R. A. Welkers, Sebastien Matamoros, Joost van Harinxma Thoe Slooten, Margriet E. M. Kraakman, et al.

    Rapid identification of the rise and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern remains critical for monitoring of the efficacy of diagnostics, therapeutics, vaccines, and control strategies. A wide range of SARS-CoV-2 next-generation sequencing (NGS) methods have been developed over the last years, but cross-sequence technology benchmarking studies have been scarce. In the current study, 26 clinical samples were sequenced using five protocols: AmpliSeq SARS-CoV-2 (Illumina), EasySeq RC-PCR SARS-CoV-2 (Illumina/NimaGen), Ion AmpliSeq SARS-CoV-2 (Thermo Fisher), custom primer sets (Oxford Nanopore Technologies (ONT)), and capture probe-based viral metagenomics (Roche/Illumina). Studied parameters included genome coverage, depth of coverage, amplicon distribution, and variant calling. The median SARS-CoV-2 genome coverage of samples with cycle threshold (Ct) values of 30 and lower ranged from 81.6 to 99.8% for, respectively, the ONT protocol and Illumina AmpliSeq protocol. Correlation of coverage with PCR Ct values varied per protocol. Amplicon distribution signatures differed across the methods, with peak differences of up to 4 log10 at disbalanced positions in samples with high viral loads (Ct values ≤ 23). Phylogenetic analyses of consensus sequences showed clustering independent of the workflow used. The proportion of SARS-CoV-2 reads in relation to background sequences, as a (cost-)efficiency metric, was the highest for the EasySeq protocol. The hands-on time was the lowest when using EasySeq and ONT protocols, with the latter additionally having the shortest sequence runtime. In conclusion, the studied protocols differed on a variety of the studied metrics. This study provides data that assist laboratories when selecting protocols for their specific setting.


  • Open Access

    Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

    by Daan W. Huntjens, Jacob A. Dijkstra, Lisanne N. Verwiel, Mirjam Slijkhuis, Paul Elbers, Matthijs R. A. Welkers, Agnes I. Veldkamp, Marianne A. Kuijvenhoven, David C. de Leeuw, Heshu Abdullah-Koolmees, et al.

    Herpes simplex virus (HSV) and cytomegalovirus (CMV) are DNA viruses that are common among humans. Severely immunocompromised patients are at increased risk of developing HSV or CMV disease due to a weakened immune system. Antiviral therapy can be challenging because these drugs have a narrow therapeutic window and show significant pharmacokinetic variability. Above that, immunocompromised patients have various comorbidities like impaired renal function and are exposed to polypharmacy. This scoping review discusses the current pharmacokinetic (PK) and pharmacodynamic (PD) knowledge of antiviral drugs for HSV and CMV treatment in immunocompromised patients. HSV and CMV treatment guidelines are discussed, and multiple treatment interventions are proposed: early detection of drug resistance; optimization of dose to target concentration by therapeutic drug monitoring (TDM) of nucleoside analogs; the introduction of new antiviral drugs; alternation between compounds with different toxicity profiles; and combinations of synergistic antiviral drugs. This research will also serve as guidance for future research, which should focus on prospective evaluation of the benefit of each of these interventions in randomized controlled trials.


  • Open Access

    Paediatric monkeypox patient with unknown source of infection, the Netherlands, June 2022

    by A Marceline Tutu van Furth, Martijn van der Kuip, Anne L van Els, Lydia Cr Fievez, Gini Gc van Rijckevorsel, Anton van Den Ouden, Marcel Jonges, Matthijs Ra Welkers

    Since May 2022, an international monkeypox (MPX) outbreak has been ongoing in more than 50 countries. While most cases are men who have sex with men, transmission is not restricted to this population. In this report, we describe the case of a male child younger than 10 years with MPX in the Netherlands. Despite thorough source tracing, a likely source of infection has not been identified. No secondary cases were identified in close contacts.


  • Open Access

    Monkeypox virus whole genome sequencing using combination of NextGenPCR and Oxford Nanopore v1

    by Matthijs Welkers, M. Jonges, Anton van Den Ouden

    Rapid genomic surveillance of monkeypox virus (MPXV) can provide valuable insights in order to guide public health interventions. Current sequencing protocols make use of direct Oxford Nanopore Sequencing. However, the obtained depth is a limiting factor which prevents multiplexing samples on a flowcell making sequencing very costly. Here, we provide the protocol for a PCR-based amplicon tiling approach (inspired by SARS-CoV-2 Midnight Protocol by Nikki Freed et. al. and the ARTIC network) for MPXV consisting of a total of 88 primer sets divided over 2 amplicon pools. The amplicon size is ~2,5kB. Our approach will increase the coverage (depth) significantly and allow for multiplexing up to 20 samples on a single Nanopore flowcell. In our experience clinical samples can be successfully sequenced with CT-values <25. Homopolymer regions will remain an issue in our approach, requiring manual curation of obtained consensus sequence genomes.


  • Open Access

    SARS-CoV-2 outbreaks in secondary school settings in the Netherlands during fall 2020; silent circulation

    by Lotte Jonker, Kimberly J Linde, Marieke LA de Hoog, Robin Sprado, Robin C Huisman, Richard Molenkamp, Bas B Oude Munnink, Wietske Dohmen, Dick Jj Heederik, Dirk Eggink, et al.

    Background In fall 2020 when schools in the Netherlands operated under a limited set of COVID-19 measures, we conducted outbreaks studies in four secondary schools to gain insight in the level of school transmission and the role of SARS-CoV-2 transmission via air and surfaces. Methods Outbreak studies were performed between 11 November and 15 December 2020 when the wild-type variant of SARS-CoV-2 was dominant. Clusters of SARS-CoV-2 infections within schools were identified through a prospective school surveillance study. All school contacts of cluster cases, irrespective of symptoms, were invited for PCR testing twice within 48 hrs and 4-7 days later. Combined NTS and saliva samples were collected at each time point along with data on recent exposure and symptoms. Surface and active air samples were collected in the school environment. All samples were PCR-tested and sequenced when possible. Results Out of 263 sampled school contacts, 24 tested SARS-CoV-2 positive (secondary attack rate 9.1%), of which 62% remained asymptomatic and 42% had a weakly positive test result. Phylogenetic analysis on 12 subjects from 2 schools indicated a cluster of 8 and 2 secondary cases, respectively, but also other distinct strains within outbreaks. Of 51 collected air and 53 surface samples, none were SARS-CoV-2 positive. Conclusion Our study confirmed within school SARS-CoV-2 transmission and substantial silent circulation, but also multiple introductions in some cases. Absence of air or surface contamination suggests environmental contamination is not widespread during school outbreaks.

  • Open Access

    The cell‐free DNA virome of 108,349 Dutch pregnant women

    by Jasper Linthorst, Moezammin M. M. Baksi, Matthijs R. A. Welkers, Erik A. Sistermans

    Objective: Viral infections during pregnancy are a major health concern to mother and fetus. By repurposing cell‐free Non Invasive Prenatal Testing (NIPT) sequencing data, we investigated prevalence and abundance of viral DNA in a cohort of 108,349 pregnant women.Method: Cell‐free DNA (cfDNA) sequencing reads that did not map to any of the human chromosomes or mitochondrial DNA of the human reference genome build GRCh38 were aligned to 224 DNA viruses selected from the NCBI refseq viral database.Results: In total 443,665 reads of viral origin were detected across 42,273 samples representing 165 viral species. Several are known to be potentially harmful during pregnancy and/or childbirth, including Cytomegalovirus, Parvovirus B19 and Hepatitis B. Viral sequences were mostly detected at very low abundance. However, several cases had exceptionally high viral loads for Parvovirus B19, Hepatitis B and others. We found statistically significant associations between presence of viral DNA and gestational age, maternal age, fetal fraction, cfDNA concentration and others.Conclusion: We demonstrate the feasibility to detect viral DNA from typical genome‐wide NIPT cfDNA sequencing and describe the main characteristics of the viral DNA in our cohort. Our dataset of detected viral sequence reads is made publicly available to guide future clinical implementations.